Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

BACKGROUND: Cisplatin-based combination chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Molecular profiling studies reveal that the PI3K/AKT/mTOR pathway is altered in a significant percentage of UCs. OBJECTIVE: We conducted a phase I trial to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Abida, Wassim, Milowsky, Matthew I., Ostrovnaya, Irina, Gerst, Scott R., Rosenberg, Jonathan E., Voss, Martin H., Apolo, Andrea B., Regazzi, Ashley M., McCoy, Asia S., Boyd, Mariel E., Bajorin, Dean F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927849/
https://www.ncbi.nlm.nih.gov/pubmed/27376132
http://dx.doi.org/10.3233/BLC-150038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927849/
https://www.ncbi.nlm.nih.gov/pubmed/27376132
http://dx.doi.org/10.3233/BLC-150038

Ejemplares similares